Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (6547)	6/23/1998 3:02:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Opala, that's my point!! Is it a U.K. drug trial? Is there no F.D.A. involvement? Who knows? The Shadow knows! Sorry, I meant XOMA knows, and I think they should explain it. Bet they would say it's only 10 people and a sort of trivial thing. That type of answer would suck! We may not need to know and the answer may be trivial but we want to know and as owners that should be good enough. I have heard that meningococcemia is rare in adults. That may be but it is not that rare in 18 yr olds. We hear all the time about 18 yr olds and 22 yr old college students getting it so it is interesting when the trial is expanded to adults. Another question that someone else mentioned to me. Why is this only being done in the U.K.Perhaps the answer is as simple as we can get 10 at one U.K. site without a great expense of having to instruct many U.S. sites in how to carry out the trial. But XOMA should supply the answer.